EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische Studie

Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer

Wungki Park iD, Anup Kasi, Alexander I Spira, Luis Paz-Ares Rodríguez, Benjamin O Herzberg, Meredith S Pelster, Anthony W Tolcher, Yasutoshi Kuboki, Shigehisa Kitano, Hirokazu Shoji, Judy S Wang, Jordan D Berlin und 24 weitere

New England Journal of Medicine · 09.04.2026 · 394 (14) · 1409-1420

DOI: 10.1056/nejmoa2600752 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift New England Journal of Medicine, erschienen am 09.04.2026. Verfasst von Wungki Park und 35 weiteren Autor:innen. Beteiligte Einrichtung: Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York. Hauptthemen laut MEDLINE: Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pancreatic Neoplasms. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Astellas Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsCarcinoma, Non-Small-Cell LungLung NeoplasmsPancreatic NeoplasmsProto-Oncogene Proteins p21(ras)Carcinoma, Pancreatic DuctalProteolysis Targeting ChimeraAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedMaximum Tolerated DoseMutationCetuximabAntineoplastic Combined Chemotherapy ProtocolsProgression-Free SurvivalInfusions, IntravenousProteolysisNeoplasm Staging

Substanzen

Antineoplastic AgentsKRAS protein, humanProto-Oncogene Proteins p21(ras)CetuximabProteolysis Targeting Chimera

Autor:innen und Institutionen

  • Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York.
  • David M. Rubenstein Center for Pancreatic Cancer Research, New York.
  • University of Kansas Medical Center, Kansas City.
  • Virginia Cancer Specialists and NEXT Oncology-Virginia, Fairfax.
  • Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid.
  • Division of Hematology/Oncology, Columbia University Irving Medical Center, New York.

ORCID-Profile: Wungki Park, Jonathan W Goldman

Förderung

  • Astellas Pharma

Zitieren

APA

Park, W., Kasi, A., Spira, A. I., Paz-Ares Rodríguez, L., Herzberg, B. O., Pelster, M. S., Tolcher, A. W., Kuboki, Y., Kitano, S., Shoji, H., Wang, J. S., Berlin, J. D., Hollebecque, A., LoRusso, P., Fountzilas, C., Cassier, P. A., Nishina, T., Sakai, D., Inagaki, C., …, & Goldman, J. W. (2026). Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer. New England Journal of Medicine, 394(14), 1409-1420. https://doi.org/10.1056/nejmoa2600752

Vancouver

Park W, Kasi A, Spira AI, Paz-Ares Rodríguez L, Herzberg BO, Pelster MS, et al. Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer. New England Journal of Medicine. 2026;394(14):1409-1420. doi:10.1056/nejmoa2600752

BibTeX
@article{Park2026,
  author = {Park, Wungki and Kasi, Anup and Spira, Alexander I and Paz-Ares Rodríguez, Luis and Herzberg, Benjamin O and Pelster, Meredith S and Tolcher, Anthony W and Kuboki, Yasutoshi and Kitano, Shigehisa and Shoji, Hirokazu and Wang, Judy S and Berlin, Jordan D and Hollebecque, Antoine and LoRusso, Patricia and Fountzilas, Christos and Cassier, Philippe A and Nishina, Tomohiro and Sakai, Daisuke and Inagaki, Chiaki and Morgensztern, Daniel and Ueno, Makoto and Jung, Minkyu and Kim, Sang-We and Jänne, Pasi A and Italiano, Antoine and You, Benoît and Macarulla, T and Fujii, Hisaki and Shetty, Aditya and Lu, Ying and Cui, Daniel and Kadam, Shilpa and Gill, Stanley C and Toyoshima, Junko and Saito, Takeshi and Goldman, Jonathan W},
  title = {Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {394},
  number = {14},
  pages = {1409--1420},
  doi = {10.1056/nejmoa2600752}
}
Kostenlos starten →